Clinical Trials

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03694262 2026-04-13

EndoBARR

30 enrolled 7 charts

DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Endometrial Neoplasms

NCT06444815 2026-04-07

STEALTH-001

Phase 1 Recruiting

60 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Mesothelioma

NCT03612791 2026-04-03

ATEZOLACC

189 enrolled

Locally Advanced Cervical Cancer

NCT03614949 2026-04-01

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

21 enrolled

Uterine Cervical Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Endometrial Neoplasms

NCT04300647 2026-03-12

SKYSCRAPER-04

172 enrolled 27 charts

Uterine Cervical Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Ovarian Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Phase 1 Recruiting

58 enrolled

GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

43 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2 Recruiting

48 enrolled

DermatologicGastrointestinalGynecologicLymphoid

Platinum-Resistant Fallopian Tube Carcinoma

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT03738228 2025-11-12

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

40 enrolled 17 charts

Uterine Cervical Neoplasms

NCT03526432 2025-10-24

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

110 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Endometrial Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03603184 2025-05-09

AtTEnd

549 enrolled

Neoplasms, Endometrial Neoplasms

NCT03353831 2025-04-06

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

574 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Ovarian Neoplasms

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03206047 2025-03-13

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Completed

12 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02891824 2025-02-11

ATALANTE

614 enrolled

Ovarian Neoplasms

NCT02876510 2025-02-04

ACTolog

GastrointestinalGynecologicHead & NeckThoracic

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03556839 2025-01-08

BEATcc

Phase 3 Active not recruiting

410 enrolled

Carcinoma, Uterine Cervical Neoplasms

NCT03946358 2024-12-20

VolATIL

GastrointestinalGynecologicHead & Neck

47 enrolled

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT03598270 2024-08-30

ANITA

417 enrolled

Ovarian Neoplasms

NCT03340376 2024-07-03

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

48 enrolled

Phase EARLY_PHASE1 Withdrawn

Uterine Cervical Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04405349 2023-12-15

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

52 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03695380 2023-08-14

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

77 enrolled

Ovarian Neoplasms

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04510584 2023-06-06

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03073525 2023-04-05

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

25 enrolled 15 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

122 enrolled

Ovarian Neoplasms

NCT02921269 2023-02-21

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

11 enrolled 11 charts

Uterine Cervical Neoplasms

NCT03386721 2023-02-21

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Phase 2 Terminated

256 enrolled 26 charts

Uterine Cervical Neoplasms

NCT03038100 2023-02-17

IMagyn050

1,301 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02914470 2021-10-19

PROLOG

12 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03394885 2021-08-12

AdORN

Phase 1/2 Completed

18 enrolled 15 charts